Clinical trials: Type 2 Diabetes Mellitus 1
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
This project aims to develop high field MR techniques to detect nerve lesions in diabetic patients. The MRI findings will be compared to results from conventional evaluations and nerve conduction studies to determine the validity…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy, Hereditary Axonal Neuropathy
- Trial name
- NCT01847937
- Where
- 5 sites in Denmark, Germany
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Local Registration Trial in China Humalog Mix 50
The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion…
- Trial name
- NCT00191581
- Testing
- Humalog Mix 50, Human Insulin Mix 50:50
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of GLP-1 on Angiogenesis
GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications…
- Trial name
- ANGIOSAFE 1 (NCT02686177)
- Testing
- Liraglutide, Metformin or sulfonylurea
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 2 Diabetes Mellitus
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
This is a Phase 1, open-label, sequential, multiple-dose, drug-drug interaction study of GK activator HMS5552 and metformin in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02597400
- Testing
- Metformin, HMS5552
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hua Medicine Limited
Diabete Type 1, Diabete Type 2
Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals With Prediabetes and Diabetes Mellitus
This randomized, double-blind, placebo-controlled clinical trial investigates the effects of the probiotic LP-LDL® (Lactobacillus plantarum ECGC 13110402) on lipid metabolism, glycemic control, inflammatory biomarkers, and…
- Conditions
- Diabete Type 1, Diabete Type 2, Prediabetes
- Trial name
- NCT07373392
- Testing
- Lactobacillus plantarum ECGC 13110402
- Where
- 2 sites in Denmark
- Volunteers
- 210 people
- Sponsor
- Aalborg University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
- Trial name
- NCT05644730
- Testing
- Fusion closed loop glucose control system
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ideal Medical Technologies
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Continuous Glucose Monitoring in Dialysis Patients With Diabetes
The primary objective of this multicenter, randomized controlled trial is to assess whether the intermittent or continuous use of continous glucose monitoring can enhance glycaemic control among dialysis patients with type 1 or…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Continuous Glucose Monitoring, Haemodialysis
- Trial name
- NCT06641765
- Testing
- Continous Glucose Monitoring
- Where
- 5 sites in Denmark
- Volunteers
- 96 people
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and healthy subjects.
- Trial name
- NCT02639130
- Testing
- Exendin [9-39]
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Type 2 Diabetes Mellitus (T2DM), Obesity
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes…
- Trial name
- NCT06279234
- Testing
- Rosuvastatin, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 1 Diabetes, Type 2 Diabetes
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port
This study investigated wearability and usability of the I-PORT™ Injection Port (I-PORT™), a new disposable injection port through which prescribed medication is injected subcutaneously from a standard syringe or pen.
- Trial name
- NCT00486109
- Testing
- I-Port(TM) Injection Port
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Patton Medical Devices
Type 2 Diabetes Mellitus
A Study of ZT002 in Healthy Participants
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
- Trial name
- NCT05491421
- Testing
- ZT002
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- QL Biopharmaceutical Australia Pty Ltd
Diabetes Mellitus, Bariatric Surgery Candidate
Paraoxonase and HDL Qualities in Glycaemia and Inflammation
The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese…
- Trial name
- PON1 (NCT02169518)
- Where
- United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Diabete Mellitus, Diabete Type 1
Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose.
- Trial name
- NCT07581197
- Testing
- Allogeneic pancreatic endocrine cell clusters
- Volunteers
- 9 people
- Sponsor
- Seraxis
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The ELG Analysis of Glucose a Correlational to Blood Glucose Assay
This study is an investigational study of the ELG medical device to monitor glucose blood level in diabetes mellitus Type 1 and 2 without blood samples in comparison to blood testing methods."Investigational" means the ELG…
- Trial name
- NCT05055804
- Testing
- ELG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- XP Technology, LLC
Type 2 Diabetes
Dog-rose, Cranberry Leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica and Sumac in Diabetes Mellitus
This study investigates the safety and combined effect of Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, Dog-rose, and Sumac on improving the glycemic profile of patients with type 2 diabetes…
- Trial name
- NCT05700513
- Testing
- Capsules containing the combination products
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Tabriz University of Medical Sciences
Diabetes (Insulin-requiring, Type 1 or Type 2)
Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol
The goal of this clinical trial is to evaluate the safety and efficacy of integrating predictive models into insulin therapy management via the user-centered glUCModel mobile app in People with Type 1 Diabetes Mellitus following…
- Trial name
- glUCModel-1 (NCT07304778)
- Testing
- glUCModel app
- Where
- 2 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Universidad Complutense de Madrid
Diabetes Mellitus
Swiss Diabetes Registry - SwissDiab Study
Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with…
- Trial name
- SwissDiab (NCT01179815)
- Where
- 4 sites in Switzerland
- Volunteers
- 1,500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01545791)
- Testing
- insulin detemir
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 1,037 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin…
- Trial name
- NCT02536859
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.